Nelson Watts, MD
Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1740238229
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 71.6% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $200,763 and has fallen 99.5% since, to $960 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 580 payments — averaging $596.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$248K
- Radius Health, Inc.$32K
- AbbVie$28K
- Novo Nordisk$12K
- Sanofi US Services Inc.$8K
- Boehringer Ingelheim$8K
- plus $10K from 26 others
Across 7 payments — averaging $1629.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$9K
- Radius Health, Inc.$2K
What the payments were for
- Consulting fees$101,17229%
- Speaking & faculty fees$201,56158%
- Travel & lodging$32,96710%
- Food & beverage$10,3553%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 360 | $247,696 |
| Radius Health, Inc. | 48 | $31,560 |
| AbbVie | 25 | $28,118 |
| Novo Nordisk | 19 | $11,979 |
| Sanofi US Services Inc. | 8 | $8,375 |
| Boehringer Ingelheim | 9 | $8,134 |
| Ipsen Bioscience Inc. | 1 | $6,270 |
| Ascendis Pharma Endocrinology Inc | 2 | $1,868 |
| Tandem Diabetes Care, Inc. | 13 | $436 |
| Medtronic(2 entities) | 25 | $342 |
| Lilly USA, LLC | 15 | $234 |
| Insulet Corporation | 11 | $187 |
| Shire North American Group Inc | 3 | $136 |
| Dexcom, Inc. | 7 | $128 |
| Cequr Corporation | 3 | $92 |
| BETA Bionics, Inc. | 3 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Sequel Med Tech, LLC | 3 | $53 |
| Mannkind Corporation | 3 | $50 |
| Amarin Pharma, Inc. | 2 | $37 |
| Amryt Pharma Holdings Ltd | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Bayer | 2 | $31 |
| AstraZeneca | 2 | $25 |
| Corcept Therapeutics | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$131,590
- EVENITY$107,865
- Tymlos$30,927
- SOTAGLIFLOZIN$8,220
- JARDIANCE$7,930
How this compares
$346,084 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 54 | $256,909 |
| ProliaDenosumab | 76 | $133,722 |
| TymlosAbaloparatide | 27 | $95,742 |
| Teriparatide | 15 | $38,590 |
| Alendronate Sodium | 753 | $4,225 |
| Calcitriol | 119 | $2,482 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 30 | $1,724 |
| Hydrochlorothiazide | 191 | $700 |
| Indapamide | 54 | $688 |
| Amiloride Hcl | 22 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $234 | $256,90954 claims |
| AmgenProlia | $247,696 | $133,72276 claims |
| Radius Health, Inc.Tymlos | $31,560 | $95,74227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cincinnati
- Shawn PeavieCincinnati$201K
- Amanda DenneyCincinnati$183K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.